Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 124NIH 47INDUSTRY 43OTHER_GOV 3NETWORK 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 41Genitourinary 36Gastrointestinal 35Breast 35Other hematologic neoplasm 32Thoracic 22CNS 18Plasma cell 17Sarcoma 16Gynecologic 16Head & Neck 13Dermatologic 9Tumor-Agnostic 7Other solid neoplasm 7Myeloid 4Endocrine 2Classical hematology 2Other neoplasm 1Other 1NET 1

Conditions

Somatostatinoma 1Pheochromocytoma 1Neuroendocrine Tumors 1Nephroma, Mesoblastic 1Neoplasms 1Myeloproliferative Disorders 1Melanoma 1Lymphoproliferative Disorders 1Ganglioneuroma 1Desmoid Tumors 1Central Nervous System Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma in Situ 1

Interventions

Temozolomide 1Etoposide 1Cisplatin 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Endocrine × 90 days × Clear all
NCT02402244 2026-05-05

Project: Every Child for Younger Patients With Cancer

Children's Oncology Group

Recruiting
75,000 enrolled
CNSDermatologicEndocrineLymphoidMyeloidNETSarcoma

Carcinoma in Situ, Ganglioneuroma, Lymphoproliferative Disorders, Melanoma, Myeloproliferative Disorders, Neoplasms, Pheochromocytoma, Central Nervous System Neoplasms, Nephroma, Mesoblastic, Desmoid Tumors, Neuroendocrine Tumors

NCT02595424 2026-05-01

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
67 enrolled 13 charts
Endocrine

Somatostatinoma, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡